ESMO22: Merck offers 5-year look at Keytruda's landmark lung cancer trials. What's next?
2nd September 2022 Uncategorised 0 ESMO22: Merck offers 5-year look at Keytruda’s landmark lung cancer trials. What’s next?
aliu
Fri, 09/02/2022 – 16:33
More: ESMO22: Merck offers 5-year look at Keytruda's landmark lung cancer trials. What's next?
Source: fierce